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Abstract
Pegylated liposomal doxorubicin (PLD) has been effective in recurrent ovarian cancer, but the ideal treatment
length is unknown. In this retrospective chart review, we examined whether prolonged treatment increased
progression-free (PFS) or overall survival (OS). Our data suggest that PLD treatment to progression is asso-
ciated with a PFS advantage compared with treatment to best response (15 vs. 10 months).
Introduction: Ovarian cancer is the ﬁfth leading cause of death in women. PLD has been effective in recurrent ovarian
cancer, but the ideal treatment length is unknown. We hypothesized that patients with regression or stabilization of
disease while receiving PLD, who continued with prolonged treatment, would have increased PFS. Patients and
Methods: A retrospective chart review was performed of women with recurrent ovarian, fallopian tube, primary
peritoneal, or uterine papillary serous carcinoma, who received 6 or more cycles of PLD without evidence of pro-
gression. Evaluation for progression was based on carcinoma antigen 125, physical examination, and imaging studies.
Results: Of the 30 patients meeting criteria for inclusion, 13 patients (43%) stopped treatment at best response
(median, 6 cycles) and 17 (57%) continued treatment until disease progression (median, 11 cycles). Patients treated to
best response experienced a signiﬁcantly shorter PFS compared with those who continued treatment until progres-
sion, median 10 versus 15 months (P ¼ .009). There was a trend toward improved OS in the prolonged therapy group
of 42.5 months (range, 12-84) versus 23 months in the standard therapy group (range, 17-98; P ¼ .56). Conclusion:
Our data suggest that prolonged PLD treatment to progression is associated with a PFS advantage compared with
treatment to best response. In the absence of toxicity, this treatment paradigm should be considered.
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Ovarian cancer is the ﬁfth leading cause of cancer death in
women with 5-year survival rates at approximately 30%.1 Despite
initially responding to cytoreductive surgery and chemotherapy,
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Currently, the treatment of recurrent disease is based on the
platinum-free interval. Evidence suggests that patients with
platinum-sensitive disease, deﬁned as progression of disease > 6
months after completion of their initial 6 cycles of platinum-based
chemotherapy, should receive combination platinum-based therapy
for their recurrence.3 The current standard for patients with
platinum-resistant disease, recurrence < 6 months after stopping
chemotherapy, is to receive single-agent, nonplatinum-based
chemotherapy. The consensus is that patients whose disease pro-
gresses during 2 consecutive therapy regimens without evidence of
clinical beneﬁts have decreased likelihood of beneﬁtting from
further therapy.4
Despite these guidelines, women whose disease relapses or who
continue to have persistent disease despite second-line regimensClinical Ovarian and Other Gynecologic Cancer December 2013 - 17
Table 1 Demographic Characteristics
Characteristic
Cycles
P6-8 (n [ 13) >8 (n [ 17)
Mean Age, Years 62 55 .08
Stage 1.0
1 or 2 0 1
3 or 4 12 15
Unknown 1 1
Optimal Resection 10 10 .4
Tumor Type .7
Ovary 12 15
Primary Peritoneal 0 2
Other 0 1
Platinum-Sensitive 9 10 .7
Line of Treatment .2
Second 6 10
Third 7 4
Fourth or greater 0 3
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18 -generally continue to be treated with further chemotherapy.
Although there are multiple agents available, there is no consensus
among oncologists on how best to manage patients who undergo
chemotherapy for recurrent disease. There is a lack of data to inform
whether it is more advantageous for patients to be treated to best
response or to disease progression (or intolerable side effects).
Pegylated liposomal doxorubicin (PLD) has been shown to be
effective in recurrent ovarian cancer. Infused once a month, PLD is
generally better tolerated and has less hematologic and gastrointes-
tinal toxicity than other agents. In the trial leading to its approval,
PLD was compared with topotecan in women with platinum-
sensitive and platinum-resistant recurrent disease. Compared with
topotecan, PLD had an 18% lower risk of death and fewer adverse
events. For platinum-sensitive patients, PLD demonstrated a 30%
reduced risk of death, with median survival of 107 weeks compared
with 70 weeks for those in the topotecan treatment arm.5 Recent
studies have suggested that it is safe to continue PLD long term.6-8
In an attempt to determine if the duration of treatment in the
context of recurrent ovarian cancer has an effect on survival, we
compared the progression free survival (PFS) of women with
recurrent disease who had received PLD for 8 or fewer cycles (PLD
was stopped because of physician or patient preference) versus
women who continued to receive PLD with regressed or stabilized
disease until progression of disease was demonstrated. We hypoth-
esized that women who continued PLD as prolonged therapy would
demonstrate a longer PFS than those who stopped PLD after the
standard 6 to 8 cycles.
Patients and Methods
This was a retrospective chart review of all patients between 1998
and 2007 at the Program in Women’s Oncology at Women and
Infants’ Hospital who received  6 cycles of PLD for recurrent
ovarian, fallopian tube, or primary peritoneal carcinoma. Patients
were excluded if they had any other type of carcinomas, dual pri-
mary carcinoma, or discontinued PLD before completion of 8 cycles
because of progression of disease or signiﬁcant side effects. This
study was approved by the institutional review board at Women and
Infants’ Hospital.
The primary outcome, PFS, was deﬁned as the number of
months from the date PLD was started to the date of disease
progression. Evidence of progression of disease was determined by
the primary provider based on one or all of the following:
increasing carcinoma antigen 125 (CA-125), radiographic evidence
of progression, or physical examination ﬁndings. These evaluations
were done at standard prechemotherapy visits every 4 weeks, with
CA-125 levels and physical examination being done routinely and
computed tomography scan added if there was clinical suspicion of
progression of disease. Overall survival (OS) was deﬁned as number
of months from the date PLD was initiated until date of death. We
included women in the “standard therapy” group if PLD was
discontinued because of patient or physician preference (in the
context of a tumor response or prolonged disease stability) and not
due to progression of disease or treatment side effects. “Prolonged
therapy” was deﬁned as more than 8 cycles of PLD before dis-
continuing treatment.
Statistical analyses were performed using MedCalc software,
version 11.1 (Ostend, Belgium). Comparisons were based on FisherClinical Ovarian and Other Gynecologic Cancer December 2013exact test or c2 analysis. PFS was modeled using the nonparametric
KaplaneMeier method.
Results
Thirty patients received at least 6 cycles of PLD at a standard
dose of 40 mg/m2 every 4 weeks without evidence of progression
and are the subject of this analysis. The median number of cycles
delivered was 9 (range, 6-28). Twenty-seven patients had ovarian
carcinoma, and 2 had a diagnosis of primary peritoneal carcinoma,
and 1 had cancer with an unknown primary site.
There were 13 patients who received “standard” therapy and 17
who received > 8 cycles of chemotherapy and constitute the
“prolonged treatment” group. The patients in the standard therapy
group were treated with PLD between 2000 and 2007, and the
patients in the prolonged therapy group were treated between 2001
and 2006. The mean age of the patients in the standard therapy
group was 62 years (range, 46-80 years) versus 55 years in the
prolonged therapy group (range, 42-77 years; P ¼ .08). Twenty-
seven patients were diagnosed with stage 3 or 4 disease, 1 with
stage 1, and 2 with unknown stage. Twenty patients underwent
optimal debulking, 10 in each group (P ¼ .4). Nineteen patients
had platinum-sensitive disease at the time of ﬁrst relapse, 9 in the
standard therapy group and 10 in the prolonged therapy group
(P ¼ .7). In the standard therapy group, 6 patients received PLD as
a second-line agent, and 7 as a third-line agent. In the prolonged
therapy group, 10 received PLD as second-line, 4 as third-line, and
3 as a fourth or greater line treatment agent (P ¼ .2). There were no
statistically signiﬁcant differences in patient characteristics between
the 2 groups (Table 1).
Among the 17 patients in the prolonged treatment group, 8
discontinued PLD because of disease progression. Seven patients
discontinued chemotherapy after standard treatment was completed
because of patient preference, not based on side effects or evidence
of progression. One patient stopped because of hip joint infection
and 1 continued to receive PLD.
Beth Cronin et alThere was a signiﬁcantly longer PFS duration among women
with prolonged PLD treatment compared with those treated with
standard therapy. The median PFS was 10 months (range, 8-24) in
the standard therapy group and 15 months (range, 7-30) in the
prolonged therapy group (P ¼ .009; Figure 1). Six patients in the
prolonged therapy group had a PFS of at least 20 months, compared
with only 1 patient in the standard group.
Although this study was not powered to detect differences in OS,
we did see a trend toward improved OS in the prolonged therapy
group of 42.5 months (range, 12-84 months) versus 23 months in
the standard therapy group (range, 17-98 months; P ¼ .56).
Pegylated liposomal doxorubicin was well tolerated by both
groups with minimal toxicities. The most common toxicity
requiring reduction in dosing but not cessation was hand-foot
syndrome (n ¼ 7). Eleven of the 30 patients had dose reductions
during treatment, 5 in the standard therapy arm and 6 in the
prolonged treatment arm.
Discussion
Most patients with recurrent ovarian cancer are not curable and
subsequent remissions are generally shorter than their ﬁrst remis-
sion. Although there are a number of trials that evaluated the role of
maintenance therapy after a ﬁrst remission, there is a paucity of
literature on maintenance therapy in second and third remissions.
In this setting, median PFS of 10 to 12 months has been reported.9
The role of PLD in the recurrent setting has been examined in
multiple trials. The Southwest Oncology Group published results of
a phase III trial in which single-agent carboplatin (CD) was
compared with CD together with PLD in recurrent ovarian cancer
patients. They reported improved PFS (12 vs. 8 months; P ¼ .03)
associated with the 2-drug regimen, but no improvement in OS (31
vs. 18 months; P ¼ .2). In addition, they reported a reduction of
platinum-associated hypersensitivity reactions when PLD was added
to CD therapy in the recurrent setting.10 Our study was not
powered to evaluate OS because we could not control for the
additional treatments that patients received after PLD. We
acknowledge this is a limitation of our study, and warrants furtherFigure 1 Kaplan-Meier Progression-Free Survival Curve for
Patients Receiving 6 to 8 Cycles of Pegylated
Liposomal Doxorubicin Versus > 8 Cycles
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Number of Cyclesresearch in the future. The recent phase III trial by Pujade-Lauraine
et al,11 comparing PLD and CD with paclitaxel and CD (CP) for
patients with platinum-sensitive recurrent ovarian cancer reported
improved PFS in the CD arm compared with the CP arm (11.3 vs.
9.4 months; P ¼ .005). In this trial, patients with stabilization of
disease or partial response after 6 cycles were allowed to continue
therapy until progression. This group found that more patients
were able to complete 6 or more cycles (85% [396] vs. 78% [391];
P < .001) in the CD arm, with 8% [36] of patients in the CD arm
receiving at least 9 cycles of CD. OS data were recently published by
Wagner et al, which demonstrated similar OS between the 2 groups
(hazard ratio, 0.99; log-rank, 0.94) with median survival of 30.7
months in the CD arm compared with 33.0 months in the CP arm.
Although the PFS survival advantage disappeared for the CD arm,
they did note that 68% [345] of patients in the CP arm received
PLD after the study, which might have contributed to the improved
OS.12 Although the literature to date has not reported a beneﬁt of
maintenance therapy in ovarian cancer, it has not been evaluated
thoroughly in the recurrent setting. Although continuing CD long-
term is not ideal, the results of these studies along with our ﬁndings
suggest a study designed to examine the PFS and OS of patients
who receive 6 cycles of CD followed by maintenance PLD until
progression compared with standard treatment with 6 cycles of CD
might be warranted.
Tanguay et al examined the role of PLD in prolonging the
platinum-free interval in a recent study. When developing platinum
resistant disease, 59 women were treated with 6 to 8 cycles of PLD,
or until disease progression was deemed to occur. Of these patients,
15 were re-treated with platinum after progression, with 12 [80%]
responding to the platinum regimen.13 Although our study did
not examine this speciﬁcally, because of our improved PFS when
PLD was continued for continued clinical beneﬁt, this could be
another option to help improve OS for patients who can tolerate
additional courses of platinum after later recurrences.
Finally, Adams et al examined response rates of PLD in women
with Breast Cancer Antigen (BRCA) mutations. They demonstrated
increased response rates to PLD in BRCA-associated ovarian cancer
compared with sporadic cases (56.5% vs. 19.5%; P ¼ .004). This
increased response also correlated with improved PFS and OS.14
Although we do not have the BRCA carrier status available for
our patient population, it might be useful to examine the potential
role for prolonged treatment with PLD in the BRCA-carrier pop-
ulation going forward.
In our study, we found continuing PLD treatment beyond the
standard treatment of 6 to 8 cycles was correlated with a PFS ad-
vantage among women with recurrent ovarian cancer. Patients who
were treated for a standard course of 6 to 8 cycles of PLD had a PFS
of 10 months and those who continued with prolonged therapy until
progression had a median PFS that was 50% longer (P ¼ .009).
Although not signiﬁcant, we did identify a trend toward improved
OS in the prolonged treatment group; 42.8 versus 22.9 months.
Although it is possible that the older age of the standard therapy
group could contribute to the improved PFS in the prolonged
treatment group, it is unlikely to play a large role because of the
generally young age of this cohort. The patients in both groups were
treated during similar time periods so the PLD regimen was likely to
be similar. Stage at initial presentation, optimal debulking, platinumClinical Ovarian and Other Gynecologic Cancer December 2013 - 19
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20 -sensitivity, and tumor type did not appear to play a role in whether
patients continued prolonged therapy. We speculate that there were
not other signiﬁcant differences between patients who discontinued
chemotherapy after 6 to 8 cycles and those who continued pro-
longed therapy. However, we do acknowledge the potential selec-
tion bias inherent in our study because it is a retrospective study and
we were unable to determine the speciﬁc reason for patient or
physician decisions leading to discontinuation of treatment. We
were able to ﬁnd basic information stating that the decision to
stop chemotherapy was not because of progression of disease, but
the speciﬁc imaging or rationale behind the decision was sometimes
vague.
We acknowledge that ours is a single-institution study with a
small sample size. However, despite its retrospective analysis, our
results suggest there is a role for continuation of treatment until
disease progression. Because one cannot predict from the outset the
patients who will beneﬁt from prolonged therapy, our study might
have inherent selection bias because only patients who responded
to PLD were the subjects of our study and patients who did not
respond favorably were excluded. In addition, our study combined
patients receiving PLD as second and third or greater lines of
treatment, which could have biased our results. Although our
numbers did not differ between the 2 groups, it would be important
to control for line of therapy when designing a prospective study.
Conclusion
Our results from a small, but similar cohort of women suggest
that continuing PLD past best clinical response might result in an
increased PFS with minimal toxicity. Future studies examining the
beneﬁt of prolonged therapy with PLD compared with other
treatment strategies in the recurrent setting might be warranted.
Clinical Practice Points
 Most women with recurrent ovarian cancer are not curable,
further affected by each subsequent remission being of shorter
duration.
 We found that continuing PLD in a maintenance fashion
allowed for a PFS advantage of 5 additional months for women
with recurrent ovarian cancer with a trend toward improved OS.Clinical Ovarian and Other Gynecologic Cancer December 2013 Our data suggest that continuation of PLD past best clinical
response might lead to increased PFS in this group of patients.
 Larger studies are necessary to further examine this question.
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